CNBC March 11, 2025
Yet another study is zeroing in on the unintended side effects of Novo Nordisk‘s semaglutide – the active ingredient in the company’s blockbuster weight loss drug Wegovy and diabetes treatment Ozempic.
But this time, the study highlights the risk of hair loss.
To be clear, semaglutide’s link to hair loss isn’t new. Clinical trials conducted by Novo Nordisk have shown a higher risk of hair loss in patients who took semaglutide compared to those who took a placebo.
Wegovy and Ozempic are part of a class of popular medications called GLP-1s, which mimic a hormone in the gut to suppress appetite and regulate blood sugar. Those drugs are known for their gastrointestinal side effects such as nausea...
Today's Sponsors
Today's Sponsor